CLINICAL TRIALS PROFILE FOR HMPL-523
✉ Email this page to a colleague
Clinical Trials for HMPL-523
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02105129 ↗ | A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523 | Completed | Hutchison Medipharma Limited | Phase 1 | The primary objective of this study is to assess the safety and tolerability of a single dose of up to 800 mg in Part A (evaluated in planned steps of 5, 20, 50, 100, 200, 300 mg under fasted conditions, followed by 300, 400, 600 and 800 mg HMPL-523 under fed conditions of a standard meal, followed by multiple doses of 200, 300, 400 and 500 mg of HMPL-523 in Part B, in healthy male volunteers. The secondary objective is to determine the pharmacokinetic profile of single (Part A) and multiple (Part B) oral doses of HMPL-523 in healthy male volunteers and to determine the preliminary effect of food (Part C） |
| NCT02503033 ↗ | A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies | Active, not recruiting | Iqvia Pty Ltd | Phase 1 | The purpose of this study is to evaluate the safety and tolerability of HMPL-523 administered to patients with relapsed or refractory Hematologic Malignancies To determine the maximum tolerated dosage/recommended phase 2 dosage and characterize the dose limited toxicities associated with HMPL-523 when administered to patients with relapsed or refractory Hematologic Malignancies |
| NCT02503033 ↗ | A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies | Active, not recruiting | Hutchison Medipharma Limited | Phase 1 | The purpose of this study is to evaluate the safety and tolerability of HMPL-523 administered to patients with relapsed or refractory Hematologic Malignancies To determine the maximum tolerated dosage/recommended phase 2 dosage and characterize the dose limited toxicities associated with HMPL-523 when administered to patients with relapsed or refractory Hematologic Malignancies |
| NCT02857998 ↗ | A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms | Unknown status | Hutchison Medipharma Limited | Phase 1 | A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms |
| NCT03483948 ↗ | Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia | Terminated | Hutchison Medipharma Limited | Phase 1 | This is a Phase I, open-label, non-randomized, multicenter study to evaluate the safety, pharmacokinetics and preliminary efficacy of HMPL-523 in combination with Azacitidine in previously untreated elderly patients with AML who are not eligible for standard induction therapy. |
| NCT03779113 ↗ | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | Recruiting | Hutchison Medipharma Limited | Phase 1 | This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for HMPL-523
Condition Name
Clinical Trial Locations for HMPL-523
Trials by Country
Clinical Trial Progress for HMPL-523
Clinical Trial Phase
Clinical Trial Sponsors for HMPL-523
Sponsor Name
